Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

2,937

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

2,937 results for “Multiple Myeloma”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov36/100

A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

ClinicalTrials.gov study NCT00531453. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

ClinicalTrials.gov study NCT03269136. IPD Sharing: NO. Countries: 2. Publications: 3.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

ClinicalTrials.gov study NCT03277105. IPD Sharing: Not stated. Countries: 18. Publications: 6.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

ClinicalTrials.gov study NCT00478218. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

ClinicalTrials.gov study NCT04151667. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma

ClinicalTrials.gov study NCT00689936. IPD Sharing: Not stated. Countries: 19. Publications: 13.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

ClinicalTrials.gov study NCT00483262. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

ClinicalTrials.gov study NCT01496118. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma

ClinicalTrials.gov study NCT04649060. IPD Sharing: NO. Countries: 11. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

ClinicalTrials.gov study NCT00833833. IPD Sharing: Not stated. Countries: 2. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

ClinicalTrials.gov study NCT01677858. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma

ClinicalTrials.gov study NCT01248455. IPD Sharing: NO. Countries: 1. Publications: 4.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma

ClinicalTrials.gov study NCT00813150. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

ClinicalTrials.gov study NCT00461045. IPD Sharing: YES. Countries: 1. Publications: 28.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

ClinicalTrials.gov study NCT02316106. IPD Sharing: Not stated. Countries: 11. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

ClinicalTrials.gov study NCT00049673. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

ClinicalTrials.gov study NCT01239368. IPD Sharing: NO. Countries: 1. Publications: 3.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Tran

ClinicalTrials.gov study NCT02513186. IPD Sharing: YES. Countries: 4. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

ClinicalTrials.gov study NCT01668719. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma

ClinicalTrials.gov study NCT03224507. IPD Sharing: NO. Countries: 1. Publications: 4.

closedIPD-NOFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record